title: Isolated hemopericardium associated with rivaroxaban: first case report.
abstract: Rivaroxaban is a novel anticoagulant approved for use in patients with atrial fibrillation for stroke prevention. It is a factor Xa inhibitor, and its activity cannot be monitored with use of the international normalized ratio. A 5.6% chance of major bleeding is associated with rivaroxaban use, including intracranial and gastrointestinal bleeds. We report the first case, to our knowledge, of isolated hemopericardium related to rivaroxaban use, which could potentially lead to death from cardiac tamponade. A 76-year-old man who was receiving rivaroxaban for atrial fibrillation presented to the emergency department with pleuritic chest pain and was found to have a hemopericardium. No signs of tamponade were evident, and his bleed remained stable after discontinuing rivaroxaban. The patient had also been taking saw palmetto, which may have contributed to the bleed by increasing rivaroxaban activity. A work-up for other causes of hemopericardium, including pacemaker lead misplacement and autoimmune disease-related pericarditis, was negative. Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of hemopericardium and rivaroxaban use. This case highlights the potential for bleeding complications associated with novel anticoagulants. Herbal products and various drugs may increase rivaroxaban levels by inhibiting P-glycoprotein and cytochrome P450 3A4 activity. Clinicians should be aware of these potential interactions with rivaroxaban and perform a review of not only the patient's drug therapy but also any herbal and food products that could alter the levels of anticoagulants. The lack of an antidote and the inability to dialyze rivaroxaban is a significant concern in situations of life-threatening bleeds. A laboratory test for monitoring rivaroxaban levels may be required for its safe use.
authors: Department of Medicine, Saint Francis Hospital and Medical Center, University of Connecticut Health Center, Hartford, Connecticut.
authors: Poojita
authors: P
authors: Shivamurthy
authors: Navkiran
authors: N
authors: Brar
authors: Michael L
authors: ML
authors: Therrien
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy; D002637:Chest Pain / Q000209:etiology; D065427:Factor Xa Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D010490:Pericardial Effusion / Q000139:chemically induced*; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban
keywords: hemopericardium; novel anticoagulant; rivaroxaban; tamponade